Coloplast has released its third-quarter financial results, showing revenue that exceeded consensus forecasts from analysts. However, the company's profit margin missed expectations during the quarter, weighed down by drag from its Biologics segment.
Further financial details, including specific figures for revenue and operating margins, were not immediately available following the headline release.
